- Q4 2023 Immunocore Holdings PLC Earnings Call TranscriptFeb 28, 2024$69.21 (-1.76%)Earnings
- Immunocore Holdings PLC at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Immunocore Holdings PLC at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Immunocore Holdings PLC Earnings Call TranscriptAug 10, 2023$61.66 (-3.67%)Earnings
- Immunocore Holdings PLC at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Immunocore Holdings PLC at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Immunocore Holdings PLC at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Q4 2022 Immunocore Holdings PLC Earnings Call TranscriptMar 01, 2023$54.05 (-1.46%)Earnings
- Immunocore Holdings PLC at Citi Virtual Oncology Leadership Summit TranscriptFeb 22, 2023
- Immunocore Holdings PLC at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Immunocore Holdings PLC at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 30, 2022
- Immunocore Holdings PLC at Jefferies London Healthcare Conference TranscriptNov 17, 2022
- Immunocore Holdings PLC PRAME Investor and Analyst Event AT ESMO 2022 TranscriptSep 09, 2022
- Q2 2022 Immunocore Holdings PLC Earnings Call TranscriptAug 10, 2022$53.95 (+4.27%)Earnings
- Immunocore Holdings PLC at Needham Healthcare Conference (Virtual) TranscriptApr 14, 2022
- Immunocore Holdings PLC To Discuss FDA Approval Call TranscriptJan 26, 2022
Immunocore Holdings PLC To Discuss FDA Approval Call Transcript
Good day, ladies and gentlemen. Thank you for standing by. Welcome to Immunocore's FDA approval of KIMMTRAK webinar. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Brian Di Donato, CFO and Head of Strategy from Immunocore. Please go ahead, sir.
Thank you, Kevin. Good morning, and good afternoon, everyone, and thank you for joining us today to discuss the FDA approval of KIMMTRAK.
Before we begin, I'd like to remind you that this call will contain forward-looking statements concerning Immunocore's future expectations, clinical development and clinical trials, regulatory approval processes, plans, prospects, corporate strategy and performance, which constitute forward-looking statements for the purpose of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated by these forward-looking statements as a result of various
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)